Comparison
Lupus vs rheumatoid arthritis
Both of these can start with sore, stiff hands, which is why they get confused early on. What they do next is different enough to change almost everything about the care. The antibody tests are where the difference shows first.
What the research found.
One review pooled the studies of anti-CCP, where it cleared 95 percent of the people who didn't have rheumatoid arthritis. A positive result came with a likelihood ratio of 12.46. It caught 67 percent of cases, so about a third of people with the disease test negative.
The 2019 classification rules for lupus start with one requirement, which is a positive ANA at a level of 1 to 80 or above. That was chosen because it catches 97.8 percent of cases. The full rule set caught 96.1 percent and cleared 93.4 percent.
Antinuclear antibodies were positive in 31.7 percent of healthy people at a 1 to 40 dilution. At 1 to 80 it was 13.3 percent. So a positive ANA on its own tells you very little about whether anybody has a disease.
One study assessed 263 patients sent to a rheumatologist for a positive ANA. Of those, 24 percent got an ANA-associated rheumatic diagnosis, and lupus made up 9.1 percent. Another 26.2 percent turned out to have no sign of any disease at all, which is more than a quarter of the group.
Rheumatoid arthritis patients were more insulin resistant than lupus patients. Insulin sensitivity was lower by 27 points, with the true value somewhere from minus 46 to minus 9. The odds of meeting the definition of insulin resistance were 2.15 times higher.
Quevedo-Abeledo and colleagues, The Journal of Rheumatology, 2020
The short answer.
Rheumatoid arthritis is mainly a joint disease, where the immune system has misread the synovium. The joint lining swells, and over years the swelling wears cartilage and bone away. Damage to the joints is what treatment is racing to prevent.
Lupus is a many-organ disease that happens to involve joints. It can affect skin, kidneys, and blood cells, and it can affect the lining of the heart and lungs, and the brain. Its joint trouble is usually painful without wearing anything away, and the kidneys are the organ that most changes the outlook.
The antibodies separate them, and they work in opposite directions. Anti-CCP clears almost everyone who doesn't have rheumatoid arthritis, so a positive result argues hard for it. ANA catches almost everyone with lupus, so a negative result argues hard against lupus, while a positive one is common in healthy people.
Side by side.
| Rheumatoid arthritis | Lupus | What it tells you | |
|---|---|---|---|
| Main target | The joint lining | Many organs at once | One is local, the other is body-wide |
| Joint damage | It wears cartilage and bone away | Usually painful without wearing away | Scans separate them over time |
| Organ risk | Heart and vessels, and lung in some | Kidney, blood, heart lining, brain | Lupus needs organ watching |
| Key antibody | Anti-CCP, which clears 95 percent | ANA, the door in, catching 97.8 percent | One clears well, the other catches well |
| A positive antibody | Argues strongly for the disease | Common in healthy people, means little alone | Read them differently |
| A negative antibody | A third of patients are negative | Argues strongly against lupus | Only one of them rules out |
| Skin involvement | Uncommon | Common, and part of the rules | Rashes point one way |
| Insulin resistance | Higher than in lupus, at 2.15 times the odds | Lower than in rheumatoid arthritis | Both raise heart risk |
What each disease targets
Rheumatoid arthritis is mainly a disease of the joints, where the immune system has misread the synovium, which is the thin lining inside a joint. It gets inflamed and thickened, and over time that swelling wears cartilage and bone away. The damage doesn't reverse, so treatment starts fast once the diagnosis is made.
Lupus is a many-organ disease that involves joints along the way. It can affect the skin, the kidneys, the blood cells, the lining around the heart and lungs, and the brain, and it can do those in almost any combination. So two people with one diagnosis between them can have illnesses that look nothing alike.
The joint trouble in lupus is usually painful without wearing the joint away. Somebody can have real lupus arthritis and normal joint scans, which is a genuinely different situation from rheumatoid arthritis. It gets misread as the pain being less real, and it isn't.
The antibodies, and why they read in opposite directions
This is the most useful thing on the page, and it's rarely explained. Anti-CCP clears almost everyone who doesn't have rheumatoid arthritis, at 95 percent, and a positive result comes with a likelihood ratio of 12.46, which means it multiplies the odds of rheumatoid arthritis by about twelve. So it's the sort of result that settles a lot of the question.
It catches only 67 percent of cases, so about a third of people with rheumatoid arthritis test negative. This test rules in well and it rules out badly. Doctors have names for those two properties, where clearing well is called specificity and catching well is called sensitivity.
ANA works the other way round. It's the first requirement in the 2019 lupus classification rules for one reason, which is that it catches 97.8 percent of cases, so almost everyone with lupus is positive. That means a negative ANA argues strongly against lupus while a positive one argues very little, because ANA is positive in 31.7 percent of healthy people at a 1 to 40 dilution and 13.3 percent at 1 to 80.
What a positive ANA usually turns out to be
The best answer to that comes from following referrals forward rather than from a textbook. One study assessed 263 patients sent to a rheumatologist for a positive ANA, where 24 percent got a diagnosis of an ANA-associated rheumatic disease. Lupus made up 9.1 percent of the group, and Sjogren disease made up another 9.1 percent.
More than a quarter of them had no sign of any disease at all, at 26.2 percent. A further 38.8 percent had a rheumatology diagnosis of some other kind, with nothing to do with their antibodies at all. So that's the real spread behind a positive result arriving in the post.
None of that makes the test useless, and it does make it a starting point rather than an answer on its own. It also explains something people find odd about the appointment that follows a positive result. A rheumatologist spends more time on your history and your exam than on the number itself.
Where they overlap
Overlapping features are common enough that rheumatology has names for them, one being mixed connective tissue disease and another undifferentiated connective tissue disease. Somebody early in an illness may fit neither box neatly, and that's an ordinary situation rather than a failure of the assessment. The names exist because the situation comes up so often.
So that's a reason for follow-up over time rather than a single visit, because the picture often clears up over months and years. A diagnosis given at a first appointment is sometimes revised later on, and that revision is the system working rather than somebody having got it wrong. More of the illness becomes visible as time passes.
It's also a reason not to lean too hard on the label at the start of things. What gets treated is the organ trouble and the inflammation in front of you, rather than the name on the letter. Both diseases get managed by watching what happens to the person who has one.
Metabolic health in both
Heart risk is raised in both conditions, by the inflammation itself and by the treatments. One study compared the two directly, where rheumatoid arthritis patients were more insulin resistant than lupus patients, with insulin sensitivity lower by 27 points and a true value somewhere from minus 46 to minus 9. The odds of meeting the definition of insulin resistance were 2.15 times higher, so rheumatoid arthritis seems to do it more.
One thing is worth knowing about that comparison. The thresholds it used came from Spanish general adults, and no threshold worked out in rheumatic disease exists. That's a limit the authors note themselves, and it applies to every insulin resistance figure quoted in rheumatology.
What follows practically is alike for both diseases. Controlling the inflammation is part of managing heart risk rather than a separate concern. Blood pressure, lipids, and metabolic health belong in a rheumatology appointment, alongside joint counts.
When each one fits.
- Think rheumatoid arthritis if joints are visibly swollen on both sides, if morning stiffness runs long, and if anti-CCP or rheumatoid factor is positive.
- Think lupus if joint pain comes with rashes or mouth ulcers, with hair loss, or with a rash after sun, and odd blood count or kidney results point that way too.
- Treat a positive ANA alone as a starting point rather than a diagnosis, because it's positive in 13.3 percent of healthy people at a 1 to 80 dilution.
- Take protein in the urine seriously and quickly in anyone with suspected lupus, and take a rising creatinine the same way, because kidney involvement changes the outlook most.
- Remember both can turn up with normal inflammation markers, so normal blood work doesn't rule either one out.
Questions patients ask.
How do the antibody tests differ?
They do opposite jobs, and that's the key to reading them. Anti-CCP cleared 95 percent of the people who didn't have rheumatoid arthritis, so a positive result argues strongly for that diagnosis, though it caught only 67 percent of cases and a third of patients test negative. ANA is the door into lupus classification for the opposite reason, because it catches 97.8 percent of cases. So a negative ANA argues strongly against lupus, while a positive one is common in healthy people.
I have a positive ANA. Do I have lupus?
Probably not. ANA is positive in 31.7 percent of healthy people at a 1 to 40 dilution, and at 1 to 80 it's 13.3 percent, which is the dilution most labs report. One study assessed 263 patients sent to a rheumatologist for a positive ANA, where 24 percent had an ANA-associated rheumatic disease and lupus made up 9.1 percent. Another 26.2 percent had no sign of any disease at all.
Do both diseases damage joints in the same fashion?
No, and this is one of the clearer differences between the two diseases. Rheumatoid arthritis wears cartilage and bone away, those changes are visible on scans, and they don't reverse once they've happened. Lupus arthritis is usually painful and inflamed without wearing anything away, so the joints hurt without being destroyed underneath the pain. That difference changes what treatment is racing to prevent in each of them.
Which one is more serious?
They're serious in different places, so the question isn't really answerable. Rheumatoid arthritis threatens joint function and it raises heart risk too, while lupus threatens organs, and kidney trouble in particular changes the outlook a great deal. So a person with mild lupus may be far better off than somebody with fierce rheumatoid arthritis, and the reverse is just as true.
Can somebody have both?
Overlapping features are common enough to have their own names, one being mixed connective tissue disease and another undifferentiated connective tissue disease. So somebody can have features that fit neither box, which happens most early on. It's a reason to be seen over time rather than once, because the picture often clears up over months and years.
Does either affect metabolic health?
Both do, and rheumatoid arthritis seems to do it more. One study compared the two directly, where rheumatoid arthritis patients were more insulin resistant than lupus patients, with insulin sensitivity lower by 27 points and the odds of meeting the definition 2.15 times higher. The thresholds that study used came from general adults, though, and no threshold worked out in rheumatic disease exists.
References.
- Nishimura K; Sugiyama D; Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of internal medicine. 2007;146:797-808. 10.7326/0003-4819-146-11-200706050-00008Diagnostic accuracy meta-analysis
- Aringer M; Costenbader K; Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2019;71:1400-1412. 10.1002/art.40930Multiphase classification criteria development with derivation
- Tan EM; Feltkamp TE; Smolen JS et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis and rheumatism. 1997;40:1601-11. 10.1002/art.1780400909Multicentre cross-sectional study of a putatively normal population across 15 international laboratories
- Fitch-Rogalsky C; Steber W; Mahler M et al. Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS ONE. 2014;9:e93812. 10.1371/journal.pone.0093812Cross-sectional retrospective analysis of a central rheumatology triage database
- Quevedo-Abeledo J; Sánchez-Pérez H; Tejera-Segura B et al. Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. The Journal of Rheumatology. 2020;48:339-347. 10.3899/jrheum.200435Cross-sectional study of 413 subjects
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.